KMDA - カマダ (Kamada Ltd.) カマダ

 KMDAのチャート


 KMDAの企業情報

symbol KMDA
会社名 Kamada Ltd (カマダ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種    医療関連(Health Care)
概要 事業概要 --   カマダは、イスラエルのバイオ医薬品企業。希少薬に焦点を当て、血漿由来タンパク質の治療薬の開発、製造を手掛ける。おもに米国とヨ―ロッパにおいて戦略的パ―トナ―や現地代理店を通じて、または直接販売にて治療薬を提供するほか、新興市場向けに販売を行う。主力製品としてGlassiaを提供する。   Kamada Ltd. (the 'Company') is a global specialty plasma-derived biopharmaceutical company with a diverse portfolio of marketed products, a robust development pipeline and industry-leading manufacturing capabilities. The Company's strategy is focused on driving profitable growth from its current commercial products, its plasma-derived development pipeline and its manufacturing expertise, while evolving into a vertically integrated plasma-derived company. The Company's two leading commercial products are GLASSIA® and KEDRRAB®. GLASSIA was the first liquid, ready-to-use, intravenous plasma-derived AAT product approved by the FDA. The Company markets GLASSIA in the U.S. through a strategic partnership with Takeda Pharmaceuticals Company Limited ('Takeda') and in other countries through local distributors. Pursuant to an agreement with Takeda, the Company will continue to produce GLASSIA for Takeda through 2021 and Takeda will initiate its own production of GLASSIA for the U.S. market in 2021, at which point Takeda will commence payment of royalties to the Company until 2040. KEDRAB is an FDA approved anti-rabies immune globulin (Human) for post-exposure prophylaxis treatment. KEDRAB is being marketed in the U.S. through a strategic partnership with Kedrion S.p.A. The Company has additional four plasma-derived products administered by injection or infusion, that are marketed through distributors in more than 15 countries, including Israel, Russia, Brazil, Argentina, India and other countries in Latin America and Asia. The Company has two leading development programs; a plasma-derived hyperimmune immunoglobulin (IgG) product as a potential treatment for coronavirus disease (COVID-19) and an inhaled AAT for the treatment of AAT deficiency for which the Company is currently conducting the InnovAATe clinical trial, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial. The Company leverages its expertise and presence in the Israeli pharmaceutical market to distribute in Israel more than 20 products that are manufactured by third parties and have recently added nine biosimilar products to its Israeli distribution portfolio, which, subject to EMA and the Israeli MOH approvals, are expected to be launched in Israel between the years 2022 and 2025. FIMI Opportunity Fund, the leading private equity investor in Israel, is the Company's lead shareholder, beneficially owning approximately 21% of the outstanding ordinary shares.
本社所在地 2 Holzman St. Weizmann Science Park Rehovot 7670402 ISR
代表者氏名
代表者役職名
電話番号
設立年月日 1990年
市場名 NASDAQ National Market System
ipoyear 2013年
従業員数 413人
url www.kamada.com
nasdaq_url https://www.nasdaq.com/symbol/kmda
adr_tso
EBITDA EBITDA ー
終値(lastsale) 6.1027
時価総額(marketcap) 245740637.0229
時価総額 時価総額 ―
売上高 売上高 --
企業価値(EV) 企業価値(EV) ー
当期純利益 当期純利益 --
決算概要 決算概要 --

 KMDAのテクニカル分析


 KMDAのニュース

   Kamada to Announce Second Quarter and First Half 2021 Financial Results and Host Conference Call on August 11, 2021  2021/08/05 11:00:00 Intrado Digital Media
REHOVOT, Israel, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that it will release financial results for the three and six months ended June 30, 2021, prior to the open of the U.S. financial markets on Wednesday, August 11, 2021.
   Former judge who told friend of drug investigation sentenced  2021/07/29 22:35:29 Albuquerque Journal
DENVER A former Weld County District Judge who tipped off a friend that a mutual acquaintance was the target of a federal drug investigation has been sentenced to a year and a day in prison. U.S. District Court Judge William Martinez sentenced 42-year-old Ryan Kamada on Wednesday, The Greeley Tribune reported. Kamada was also []
   Rabies Immunoglobulin Market Size Competitive Strategies & Forecasts Research Report 2021-2028 Sanofi, Shanghai RAAS, KEDRAB, Bharat Serum, Kamada  2021/07/27 07:16:01 OpenPR
Rabies is a zoonotic viral disease caused due to animal bites. The disease is mainly transmitted from domestic and wild animals such as bats, foxes, racc, cats, or dogs and infects humans upon contacting infected animal saliva. Its incubation period
   Alpha-1 Antitrypsin Drugs Market 2021 SWOT Analysis, Competitive Landscape and Significant Growth | Top Brands:Baxter, Arrowhead Research Corporation, Kamada, CSL Behring, Applied Genetic Technolog  2021/07/24 13:06:43 Jumbo News
This report studies the Alpha-1 Antitrypsin Drugs Market with many aspects of the industry such as market size, market status, market trends and forecast. The report also provides brief information on competitors and opportunities for specific growth with the key market drivers. Find the comprehensive analysis of the Alpha-1 Antitrypsin Drugs market segmented by company, []
   The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street  2021/07/20 12:19:55 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 19) Cytokinetics, Incorporated (NASDAQ: CYTK ) ( announced topline results from Cohorts 1 and 2 of the Phase 2 study of CK-274 in obstructive outflow disease in hypertrophic cardiomyopathy) Forward Pharma A/S (NASDAQ: FWP ) ResMed Inc. (NYSE: NRMD) Legend Biotech Corporation (NASDAQ: LEGN ) Moderna, Inc. (NASDAQ: MRNA ) ( extended gains on recent momentum) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 19) 4D pharma plc (NASDAQ: LBPS ) Adaptimmune Therapeutics plc (NASDAQ: ADAP ) Adverum Biotechnologies, Inc. (NASDAQ: ADVM ) Aerovate Therapeutics, Inc. (NASDAQ: AVTE ) (IPOed June 30) Agile Therapeutics, Inc. (NASDAQ: AGRX ) Allena Pharmaceuticals, Inc. (NASDAQ: ALNA ) Alzamend Neuro, Inc. (NASDAQ: ALZN ) Aptose Biosciences Inc. (NASDAQ: APTO ) ARCA biopharma, Inc. (NASDAQ: ABIO ) Ascendis Pharma A/S (NASDAQ: ASND ) Assembly Biosciences, Inc.
   Hedge Funds Are Selling Kamada Ltd (KMDA)  2021/06/18 14:24:28 Insider Monkey
   Global Emphysema Treatment Market 2021 Report Covered by Top Key Players Pulmonx, Bioxyne, Intrexon, Icure Pharmaceuticals, Kamada, Emphasys Medical, Pfizer  2021/06/13 07:15:45 Jumbo News
Global Emphysema Treatment Market 2021 by Company, Regions, Type and Application, Forecast to 2026 recently launched by MarketsandResearch.biz endows you with the best market research and analysis performed with the advanced tools and techniques. The market report is formulated with the most excellent and superior tools for collecting, recording, estimating, and analyzing market data of []
   Regulatory actions for June 2, 2021  2021/06/02 15:00:00 BioWorld
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Amryt, BMS, Boehringer, Inmune, Janssen, Kamada, Karyopharm, Kedrion, Novartis, RDIF, Roche, Scynexis, Sinovac, Soleno, Stealth, Tetra, Zealand.
   Kedrion and Kamada Announce FDA Approval of KEDRAB Label Update, Confirming Safety and Effectiveness in Children  2021/06/02 11:00:00 Wallstreet:Online
Label Expansion Differentiates KEDRAB as the First and Only Human Rabies Immune Globulin (HRIG) Available in the U.S. to be Clinically Studied in Children KEDRAB Product Label Now Includes Patients of All Ages New FDA Approval Based on Safety and Effectiveness of KEDRAB in the Pediatric Population Demonstrated in a U.S. Post Marketing Clinical Trial World Health
   Kedrion and Kamada Announce FDA Approval of KEDRAB® Label Update, Confirming Safety and Effectiveness in Children  2021/06/02 00:00:00 BioSpace
World Health Organization Estimates up to 40 Percent of People Exposed to a Suspected Rabid Animal are Children Under 15 Years of Age
   Hedge Funds Are Selling Kamada Ltd (KMDA)  2021/06/18 14:24:28 Insider Monkey
   Global Emphysema Treatment Market 2021 Report Covered by Top Key Players Pulmonx, Bioxyne, Intrexon, Icure Pharmaceuticals, Kamada, Emphasys Medical, Pfizer  2021/06/13 07:15:45 Jumbo News
Global Emphysema Treatment Market 2021 by Company, Regions, Type and Application, Forecast to 2026 recently launched by MarketsandResearch.biz endows you with the best market research and analysis performed with the advanced tools and techniques. The market report is formulated with the most excellent and superior tools for collecting, recording, estimating, and analyzing market data of []
   Regulatory actions for June 2, 2021  2021/06/02 15:00:00 BioWorld
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Amryt, BMS, Boehringer, Inmune, Janssen, Kamada, Karyopharm, Kedrion, Novartis, RDIF, Roche, Scynexis, Sinovac, Soleno, Stealth, Tetra, Zealand.
   Kedrion and Kamada Announce FDA Approval of KEDRAB Label Update, Confirming Safety and Effectiveness in Children  2021/06/02 11:00:00 Wallstreet:Online
Label Expansion Differentiates KEDRAB as the First and Only Human Rabies Immune Globulin (HRIG) Available in the U.S. to be Clinically Studied in Children KEDRAB Product Label Now Includes Patients of All Ages New FDA Approval Based on Safety and Effectiveness of KEDRAB in the Pediatric Population Demonstrated in a U.S. Post Marketing Clinical Trial World Health
   Kedrion and Kamada Announce FDA Approval of KEDRAB® Label Update, Confirming Safety and Effectiveness in Children  2021/06/02 00:00:00 BioSpace
World Health Organization Estimates up to 40 Percent of People Exposed to a Suspected Rabid Animal are Children Under 15 Years of Age

 関連キーワード  (― 米国株 カマダ KMDA Kamada Ltd.)

 twitter  (公式ツイッターやCEOツイッターなど)